Events Archives - Page 27 of 128

3 minute read

Sensei Biotherapeutics Reports Clinical Data For SNS-101 At 2023 SITC Annual Meeting

November 3, 4:06 PM

- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts - - First

SNSE

2 minute read

Kineta Presents New Preclinical Data On Lead Anti-CD27 Monoclonal Antibody At The Society For Immunotherapy Of Cancer’ 38th Annual Meeting

By Benzinga Newsdesk

November 3, 4:01 PM

Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and SpecificityDrives Strong T Cell Activation and Proliferation as well as NK Cell ActivationDemonstrated In Vivo Antitumor Efficacy as a Single Agent and

3 minute read

Medicenna Presents Preclinical Data On MDNA113, Its Targeted Metalloprotease Activated SuperKine At The 38th Annual Meeting Of The Society For Immunotherapy Of Cancer

By Benzinga Newsdesk

November 3, 12:13 PM

Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a

MDNA

2 minute read

IN8bio Presents Data Update From Induced Pluripotent Stem Cell Platform At The Society For Immunotherapy Of Cancer 38th Annual Meeting

By Benzinga Newsdesk

November 3, 12:12 PM

This data represents a step forward in developing next-generation ‘off-the-shelf' iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential to produce billions

INAB

4 minute read

Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting

By Benzinga Newsdesk

November 3, 12:12 PM

– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma –– Preclinical data presented for novel

SGEN

3 minute read

TriSalus Life Sciences Presents Data For SD-101 Delivered By TriSalus Infusion System For Pancreatic Adenocarcinoma At The Society For Immunotherapy Of Cancer Annual Meeting

By Benzinga Newsdesk

November 3, 12:11 PM

– New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist in pancreatic tumors –TriSalus Life Sciences®

TLSI

2 minute read

Beyond Cancer Presents First-In-Human Clinical Data For Ultra-High Concentration Nitric Oxide Therapy In Solid Tumors During The Society For Immunotherapy Of Cancer 2023 Annual Meeting

By Benzinga Newsdesk

November 3, 12:10 PM

First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic response previously

XAIR

3 minute read

Molecular Partners Presents Updated Data From Ongoing Phase 1 Trial of MP0317 Monotherapy In Patients With Advanced Solid Tumors At The 2023 SITC Annual Meeting

By Benzinga Newsdesk

November 3, 12:09 PM

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned

MOLN

1 minute read

Cidara Therapeutics Presents Preclinical Data On Novel Drug-Fc Conjugate CBO421 At SITC’s 38 Annual Meeting

By Benzinga Newsdesk

November 3, 12:09 PM

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of

CDTX

2 minute read

MiNK Therapeutics Presents Clinical Activity And Long-Term Persistence Of Allogeneic iNKT Cells In Solid Tumors At SITC 2023

By Benzinga Newsdesk

November 3, 12:08 PM

Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic

INKT